Evaluation of factors affecting overall survival in patients with gastric adenocarcinoma - Single center experience

Yıl 2022, Cilt: 3 Sayı: 3, 297 - 302, 30.11.2022

Anıl Can Coşkun Zeynep Gök Sargın Güray Ceylan

https://doi.org/10.48176/esmj.2022.89

Öz

Background: Gastric cancer is the fifth most frequently diagnosed malignancy worldwide and has a high mortality rate because it is often at an advanced stage at the time of diagnosis. We aimed to investigate the overall survival (OS) outcomes and prognostic factors associated with survival in gastric cancer patients followed-up in our center.

Methods: The data of 200 patients with gastric adenocarcinoma followed between January 2013 and September 2020 were evaluated retrospectively.

Results: The male/female ratio of the cases was 2.3:1, and the median age was 63,83± 11,88 years. It was observed that 7% of the patients were stage 1, 12.5% were stage 2, 23% were stage 3, and 55.5% were stage 4. Age (≤60 and >60), gender, tumor histological subtype, tumor size (≤5 and >5 cm), tumor location (antrum, corpus, cardia), TNM stage (1, 2, 3, or 4), lymphovascular invasion(present or absent), perineural invasion (present or absent), history of surgery (operated, inoperable), surgical margin status (positive or negative), presence of progression (present or absent) and presence of metastases (present or absent) were investigated as prognostic factors that may affect the OS. According to the univariate analysis of factors, early TNM stage, absence of metastases, adjuvant CRT, and FUFA regimen were associated with improved OS (p=0.001). Only, early T stage [OR: 1.38 (95% CI, 1.046-1,822)], (p=0.023) and adjuvant CT [OR: 4.5 (95% CI, 1.554-13.046)], (p=0.006) were related with increased OS in the multivariate logistic regression analysis of prognostic factors.

Conclusions: TNM stage, adjuvant CRT, chemotherapy regimen, and curative surgical resection significantly affected OS in patients with gastric adenocarcinoma.

Anahtar Kelimeler

Gastric adenocancer, Chemoradiotherapy, Overall survival, TNM Staging

Mide adenokarsinomlu hastalarda genel sağkalımı etkileyen faktörlerin değerlendirilmesi - Tek merkez deneyimi

Öz

Giriş: Mide kanseri, dünya çapında en sık teşhis edilen beşinci malignite olup, tanı anında sıklıkla ileri evrede olması nedeniyle mortalitesi yüksektir. Bu çalışmada merkezimizde takip ve tedavi edilen mide kanseri hastalarında genel sağkalım (GS) sonuçlarını ve sağ kalım ile ilişkili prognostik faktörleri araştırmayı amaçladık.

Yöntemler: Ocak 2013 - Eylül 2020 yılları arasında takip edilen mide adenokanseri olan 200 hastanın verileri retrospektif olarak değerlendirilip kaydedildi.

Bulgular: Çalışmaya alınan hastaların erkek/kadın oranı 2.3:1 ve ortanca yaş 63,83± 11,88 yıl olarak tespit edildi. Hastaların %7'sinin evre 1, %12,5'inin evre 2, %23'ünün evre 3 ve %55,5'inin evre 4 olduğu izlendi. Yaş (≤60 ve >60), cinsiyet, tümör histolojik alt tipi, tümör boyutu (≤) 5 ve >5 cm), tümör yerleşimi (antrum, korpus, kardia), TNM evresi (1, 2, 3 veya 4), lenfovasküler invazyon (var veya yok), perinöral invazyon (var veya yok), operasyon öyküsü (opere, inoperabl), cerrahi sınır durumu (pozitif veya negatif), progresyon varlığı (var veya yok) ve metastaz varlığı (var veya yok) GS'yi etkileyebilecek prognostik faktörler olarak araştırıldı. Faktörlerin tek değişkenli analizine göre; erken TNM evresi, metastaz yokluğu, adjuvan KRT ve FUFA rejimi almak, artmış GS ile ilişkiliydi (p=0.001). Sadece erken T evresi [OR: 1.38 (%95 CI, 1.046 1.822)], (p=0.023) ve adjuvan KT almak [OR: 4.5 (%95 CI, 1.554-13.046)], (p=0.006) prognostik faktörlerin çok değişkenli lojistik regresyon analizinde artan GS ile ilişkiliydi.

Sonuç: Mide adenokarsinomlu hastalarda TNM evresi, adjuvan KRT, kemoterapi rejimi ve küratif cerrahi rezeksiyon GS'yi önemli ölçüde etkiledi.

Anahtar Kelimeler

Mide adenokanseri, Kemoradyoterapi, Genel sağkalım, TNM Evrelemesi

Kaynakça

• 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/CAAC.21492
• 2. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (London, England). 2015;385(9972):977-1010. doi:10.1016/S0140-6736(14)62038-9
• 3. Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63(5):1279-1285. doi:10.1016/J.IJROBP.2005.05.005
• 4. Macdonald JS. Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol. 2005;90(3):166-170. doi:10.1002/JSO.20223
• 5. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327-2333. doi:10.1200/JCO.2011.36.7136
• 6. Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47(11):1295-1302. doi:10.1007/S00595-017-1493-Y
• 7. Aznab M, Beiki O, pia KE, Setayeshi K, Hesami MA, Vrae H. Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy. J Gastrointest Cancer. 2017;48(1):31-37. doi:10.1007/S12029-016-9868-7
• 8. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268-273. doi:10.1200/JCO.2011.39.1953
• 9. Chang JS, Koom WS, Lee Y, Yoon HI, Lee HS. Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: is radiotherapy necessary after D2-dissection? World J Gastroenterol. 2014;20(36):12900-12907. doi:10.3748/WJG.V20.I36.12900
• 10. Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104(3):361-366. doi:10.1016/J.RADONC.2012.08.024
• 11. Canyilmaz E, Soydemir G, Serdar L, et al. Evaluation of prognostic factors and survival results in gastric carcinoma: single center experience from Northeast Turkey. Int J Clin Exp Med. 2014;7(9):2656. Accessed January 1, 2022. /pmc/articles/PMC4211773/
• 12. Agolli L, Enrici RM, Osti MF. Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients? World J Gastroenterol. 2016;22(3):1131. doi:10.3748/WJG.V22.I3.1131
• 13. Aoyama T, Yoshikawa T, Fujikawa H, et al. Prognostic factors in stage IB gastric cancer. World J Gastroenterol. 2014;20(21):6580-6585. doi:10.3748/WJG.V20.I21.6580
• 14. Wang Y, Zhang J, Guo S, et al. Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis. Clin Transl Oncol. 2019;21(11):1499-1509. doi:10.1007/S12094-019-02078-Y
• 15. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808-816. doi:10.1097/01.SLA.0000143245.28656.15
• 16. Ott K, Blank S, Becker K, et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. Langenbeck’s Arch Surg. 2013;398(2):239-249. doi:10.1007/S00423-012-1039-0
• 17. Stiekema J, Trip AK, Jansen EPM, et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol. 2014;21(4):1107-1114. doi:10.1245/S10434-013-3397-4
• 18. Deng J, You Q, Gao Y, et al. Prognostic value of perineural invasion in gastric cancer: a systematic review and meta-analysis. PLoS One. 2014;9(2). doi:10.1371/JOURNAL.PONE.0088907
• 19. Yao JC, Mansfield PF, Pisters PWT, et al. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003;21(4):223-227. doi:10.1002/SSU.10040 20. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J cancer. 2015;136(5):E359-E386. doi:10.1002/IJC.29210
• 21. Roviello F, Marrelli D, De Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90(9):1113-1119. doi:10.1002/BJS.4164
• 22. Yusefi AR, Lankarani KB, Bastani P, Radinmanesh M, Kavosi Z. Risk Factors for Gastric Cancer: A Systematic Review. Asian Pac J Cancer Prev. 2018;19(3):591. doi:10.22034/APJCP.2018.19.3.591
• 23. Baba H, Maehara Y, Takeuchi H, et al. Effect of lymph node dissection on the prognosis in patients with node-negative early gastric cancer. Surgery. 1995;117(2):165-169. doi:10.1016/S0039-6060(05)80080-7
• 24. Zhao LY, Zhang WH, Chen XZ, et al. Prognostic Significance of Tumor Size in 2405 Patients With Gastric Cancer: A Retrospective Cohort Study. Medicine (Baltimore). 2015;94(50). doi:10.1097/MD.0000000000002288
• 25. E Orsenigo, M Carlucci, M Braga, V Tomajer, S Di Palo, A Tamburini, V Di Carlo CS. Prognostic factors of gastric neoplasms: experience with 1,074 cases undergoing surgical treatment at a single center. Suppl Tumori. 2005;4(3):86-87.
• 26. Wang W, Sun XW, Li CF, et al. Comparison of the 6th and 7th editions of the UICC TNM staging system for gastric cancer: results of a Chinese single-institution study of 1,503 patients. Ann Surg Oncol. 2011;18(4):1060-1067. doi:10.1245/S10434-010-1424-2
• 27. Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192(3):296-300. doi:10.1016/J.AMJSURG.2006.03.004
• 28. Tuncer İ, Uygan İ, Kösem M, Özen S, Uğraş S, Türkdoğan K. Van ve Çevresinde Görülen Üst Gastrointestinal Sistem Kanserlerinin Demografik ve Histopatolojik Özellikleri*. Published online 2001.
• 29. Piso P, Werner U, Lang H, Mirena P, Klempnauer J. Proximal versus distal gastric carcinoma--what are the differences? Ann Surg Oncol. 2000;7(7):520-525. doi:10.1007/S10434-000-0520-0
• 30. Park JC, Lee YC, Kim JH, et al. Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: a single-center, large-volume study in Korea. Ann Surg Oncol. 2010;17(3):829-837. doi:10.1245/S10434-009-0785-X
• 31. Cenitagoya GF, Bergh CK, Klinger-Roitman J. A prospective study of gastric cancer. “Real” 5-year survival rates and mortality rates in a country with high incidence. Dig Surg. 1998;15(4):317-322. doi:10.1159/000018645
• 32. Talamonti MS, Kim SP, Yao KA, et al. Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery. 2003;134(4):720-727. doi:10.1016/S0039-6060(03)00337-4
• 33. Maehara Y, Kabashima A, Koga T, et al. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000;128(3):408-416. doi:10.1067/MSY.2000.107265
• 34. Chambers WM, Khan U, Gagliano A, Smith RD, Sheffield J, Nicholls RJ. Tumour morphology as a predictor of outcome after local excision of rectal cancer. Br J Surg. 2004;91(4):457-459. doi:10.1002/BJS.4504
• 35. Bora H, Unsal D, Akmansu M. Results of chemoirradiation after curative resection of locally advanced gastric cancer. Int J Clin Pract. 2004;58(5):451-456. doi:10.1111/J.1368-5031.2004.00024.X
• 36. Henning GT, Schild SE, Stafford SL, et al. Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2000;46(3):589-598. doi:10.1016/S0360-3016(99)00446-0
• 37. Jackson C, Cunningham D, Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2009;20 Suppl 4(SUPPL. 4). doi:10.1093/ANNONC/MDP122
• 38. Ge L, Hou L, Yang Q, et al. A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer. Medicine (Baltimore). 2019;98(7). doi:10.1097/MD.0000000000014478
• 39. HACIBEKIROGLU I, KODAZ H, ERDOGAN B, et al. Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer. Mol Clin Oncol. 2015;3(5):1160-1164. doi:10.3892/MCO.2015.592
• 40. Kim YJ, Goh PG, Kim ES, et al. [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy]. Korean J Gastroenterol. 2011;58(6):311-317. doi:10.4166/KJG.2011.58.6.311